CONCLUSIONS: The approach produces an estimation of a lower bound for cost savings concerning the treatment of diabetes related complications in a 30-year time frame. These savings alone do not prove cost efficiency of the INCA approach. Further work is needed to improve the approximation and to include indirect and intangible costs.
PMID: 17656150 [PubMed – as supplied by publisher] (Source: International Journal of Medical Informatics).